Nuclear medicine is a branch of medical imaging and treatment that uses small amounts of radioactive materials to diagnose and treat disease. Unlike a standard X-ray or CT scan, which shows the structure of your bones and organs, nuclear medicine reveals how those organs are actually functioning at a molecular level. This makes it uniquely powerful for catching problems early, often before physical changes show up on other types of scans.
How Nuclear Medicine Works
The process starts with a radiopharmaceutical, a compound made of two parts: a radioactive atom (the tracer) and a molecule designed to travel to a specific target in your body. That targeting molecule might be a modified sugar, a small protein, or an antibody. Once injected, swallowed, or inhaled, the compound travels through your bloodstream and accumulates wherever it’s designed to go. Cancer cells that consume glucose rapidly, for instance, will soak up a radiolabeled sugar molecule far more than surrounding healthy tissue.
As the tracer settles into its target, the radioactive atom decays and emits tiny bursts of energy in the form of gamma rays. A specialized camera outside your body detects those rays and maps exactly where the tracer has concentrated. The result is a three-dimensional image showing not what your organs look like, but what they’re doing: how actively your heart muscle is pumping, whether your bones are repairing a hidden fracture, or where a tumor is spreading.
This ability to image metabolism is something no other imaging method reliably provides. Ultrasound, CT, and MRI can show motion and some organ function, but imaging the actual chemical activity inside cells is a capability that belongs almost exclusively to nuclear medicine.
The Two Main Types of Scans
Nuclear medicine imaging falls into two main categories: SPECT and PET. Both produce 3D images, but they work differently and tend to be used for different conditions.
SPECT Scans
SPECT (single-photon emission computed tomography) uses tracers that emit single gamma rays as they decay. A set of gamma cameras rotates in a tight circle around you as you lie on a bed, collecting signals from every angle to build a detailed picture. SPECT is the workhorse for heart imaging, particularly for diagnosing and tracking blocked coronary arteries. It’s also used to evaluate bone disorders, gallbladder disease, intestinal bleeding, and kidney function. More recently, SPECT agents have been developed to help diagnose Parkinson’s disease and distinguish it from other movement disorders and dementias.
The most commonly used tracer in SPECT imaging is technetium-99m, which accounts for a large share of all nuclear medicine procedures worldwide. It has a six-hour half-life, meaning half its radioactivity disappears every six hours. That window is long enough to complete imaging but short enough that the radiation clears your body relatively quickly. Technetium-99m can be attached to different molecules to image the brain, bones, lungs, kidneys, thyroid, heart, liver, spleen, and more.
PET Scans
PET (positron emission tomography) uses a different type of radioactive decay. The tracers emit positrons, which are particles identical to electrons but with a positive charge. When a positron meets an electron in your body, the two annihilate each other and release two gamma rays that shoot off in exactly opposite directions. The PET scanner’s ring of detectors picks up both rays simultaneously, which allows for extremely precise localization of the tracer.
PET’s primary role is in cancer care. It detects tumors, monitors how they respond to treatment, and identifies whether cancer has spread to other parts of the body. The most widely used PET tracer is a radiolabeled form of glucose called FDG. Because aggressive cancers tend to burn through glucose faster than normal tissue, they light up on a PET scan. This principle, that a tumor’s aggressiveness roughly parallels its glucose consumption, makes PET scans invaluable for staging and treatment planning. PET has also expanded into brain imaging, where an FDA-approved tracer now helps diagnose Alzheimer’s disease during a patient’s lifetime, something that was previously only confirmable after death.
Nuclear Medicine as Treatment
Nuclear medicine isn’t limited to taking pictures. The same radioactive materials that help locate disease can also be used to treat it, by swapping the imaging isotope for one that delivers a higher, cell-killing dose of radiation directly to diseased tissue.
The most established example is radioactive iodine for thyroid conditions. Your thyroid naturally absorbs iodine, so a radioactive form of it concentrates almost entirely in thyroid tissue. At a diagnostic dose, it produces images. At a therapeutic dose, it destroys overactive or cancerous thyroid cells while largely sparing the rest of your body.
A newer and rapidly growing application targets advanced prostate cancer. Prostate cancer cells produce a surface marker called PSMA. Radioactive molecules designed to latch onto PSMA can first be used with a PET scan to confirm the cancer expresses this marker, and then a therapeutic version of the same molecule delivers targeted radiation to those cancer cells wherever they’ve spread. This approach is approved for patients whose cancer has progressed after hormonal therapies and chemotherapy.
The Theranostic Approach
This strategy of pairing a diagnostic scan with a targeted treatment using the same or a very similar molecule has a name: theranostics. It represents one of the most significant shifts in how cancer is managed. The idea is straightforward. You first image the patient with a low-dose version of a compound to confirm their disease will respond, then treat with a higher-dose version that delivers radiation directly to the tumor cells. If the scan shows the tracer isn’t accumulating in the cancer, you know the therapy won’t work either, and you avoid an ineffective treatment.
Theranostics is already established for thyroid cancer, neuroendocrine tumors, prostate cancer, and neuroblastoma. In each case, the diagnostic and therapeutic isotopes can be different forms of the same element (like iodine-123 for imaging and iodine-131 for treatment) or entirely different elements attached to the same targeting molecule.
What to Expect During a Scan
For most diagnostic nuclear medicine procedures, you’ll receive the tracer through an injection into a vein, though some tracers are swallowed or inhaled. After that, there’s typically a waiting period, anywhere from a few minutes to a few hours, while the tracer travels to its target. During the scan itself, you lie still on a table while the camera captures images. The process is painless and usually takes 20 to 45 minutes, depending on the type of exam.
Preparation varies by procedure. A heart stress test may require you to avoid caffeine for 24 hours beforehand. A thyroid scan might involve stopping certain medications. Your imaging facility will give you specific instructions ahead of time. After a diagnostic scan, the small amount of radioactive material passes out of your body naturally through urine and normal decay, usually within hours to a day or two.
Therapeutic procedures involve higher doses and sometimes require brief isolation precautions afterward to protect the people around you, particularly young children and pregnant women. The specifics depend on which isotope is used and how much is given.
Radiation Exposure in Context
Any procedure involving radioactive materials raises a reasonable question about safety. The effective radiation dose from most nuclear medicine scans falls between 0.3 and 20 millisieverts (mSv), a unit used to measure radiation exposure. For comparison, the average person absorbs about 3 mSv per year just from natural background radiation (cosmic rays, radon in the soil, and trace radioactivity in food). A standard chest X-ray delivers roughly 0.01 to 0.1 mSv.
So a nuclear medicine scan typically involves a dose comparable to one to several years of natural background exposure. The guiding safety principle across the field is ALARA: “as low as reasonably achievable.” This means using the smallest tracer dose that still produces a useful image, minimizing the time spent near any radioactive source, and using shielding wherever practical. For patients, the diagnostic benefit of the scan almost always far outweighs the small additional radiation exposure.
How It Differs From Other Imaging
The core distinction is function versus structure. A CT scan or MRI excels at showing detailed anatomy: the size of a tumor, the shape of a bone fracture, the structure of brain tissue. Nuclear medicine shows what’s happening at the cellular level: whether a tumor is metabolically active or dormant, whether blood flow to a section of heart muscle is adequate, whether a kidney is filtering properly.
In practice, these approaches are increasingly combined. PET/CT scanners overlay a PET scan’s functional data onto a CT scan’s anatomical detail, giving doctors both pieces of information in a single session. PET/MRI systems do the same with magnetic resonance imaging. This fusion of structural and functional information makes it possible to pinpoint not just where something abnormal is, but exactly what it’s doing and how aggressively it needs to be treated.